Summary
A population survey of a common folate-sensitive fragile site, fra(3)(p14.2), has been carried out on PHA-stimulated peripheral lymphocytes of patients with cancer and other diseases, under both culture conditions of folate deprivation and aphidicolin treatment. Overall findings regarding variability of expressivity due to age and sex were very similar to those obtained in a healthy population. The expression of fra(3)(p14.2) by folate deficient condition appeared hardly influenced by such exogenous factors as tobacco smoking habit, past histories of radiotherapy and chemotherapy, while it was associated with the unfavorable prognosis of cancers. Furthermore, proportion of those with higher expression was slightly but significantly larger in both lung and breast cancer patients. These findings suggest that some factors relevant to the expression of fra(3)(p14.2) may be associated with development and progression of certain kinds of cancer.
Similar content being viewed by others
Article PDF
References
Cutler SJ, Ederer F (1958): Maximum utilization of the life table method in analyzing survival. J Chron Dis8: 699–712
Furuya T, Ochi H, Watanabe S (1989): Common fragile sites in chromosomes of bone marrow cells and peripheral blood lymphocytes from healthy persons and leukemia patients. Cancer Genet Cytogenet43: 131–138
Glover TW, Berger C, Coyle J, Echo B (1984): DNA polymerase inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet67: 136–142
Glover TW, Coyle-Morris JF, Li FP, Brown RS, Berger CS, Gemmill RM, Hecht F (1988): Translocation t(3;8)(p14.2;q24.1) in renal cell carcinoma affects expression of the common fragile site at 3p14 (FRA3B) in lymphocytes. Cancer Genet Cytogenet31: 69–73
Green, RJ, Phillips DL, Chen ATL, Reidy JA, Ragab AH (1988): Effects of folate in culture medium on common fragile sites in lymphocyte chromosomes from normal and leukemic children. Hum Genet81: 9–12
Kampmann T, Schmidt A, Rüdiger HW, Tan TL, Passarge E (1990): No difference in expression of chromosomal fragile sites in patients with solid malignant tumours and normal controls. Genes Chromos Cancer2: 44–47
Kao-Shan C, Fine RL, Wang-Peng J, Lee EC, Chabner BA (1987): Increased fragile sites and sister chromatid exchanges in bone marrow and peripheral blood of young cigarette smokers. Cancer Res47: 6278–6282
Magnus EM (1967): Folate activity in serum and red cell of patients with cancer. Cancer Res27: 490–497
Murata M, Otsuka M, Hayakawa Y, Takahashi E, Tsuji H, Hori T (1990): A population cytogenetic study of a common fragile site, fra(3)(p14), in a healthy population. Jpn J Human Genet35: 291–302
Porfirio B, Paladini P, Maccherini M, Gotti G, Cintorino M, De Marchi M (1989): Patients with different lung cancers show normal expression of fra(3)(p14) in aphidicolin-treated lymphocyte cultures. Cancer Genet Cytogenet43: 95–101
Rao PN, Heerema NA, Palmer CG (1988): Expression of fragile sites in childhood acute lymphoblastic leukemia patients and normal controls. Hum Genet79: 329–334
Sager R (1989): Tumor suppresser genes: The puzzle and the promise. Science246: 1406–1412
Sato T, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y (1991): Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res51:5794–5799
Tedeschi B, Porfirio B, Vernole P, Caporossi D, Dallpiccola B, Nicoletti B (1987): Common fragile sites: Their prevalence in subjects with constitutional and acquired chromosomal instability. Am J Med Genet27: 471–482
Yamakawa K, Morita R, Takahashi E, Hori T, Ishikawa J, Nakamura Y (1991): A deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma. Cancer Res51: 4707–4711
Yokoyama S, Yamakawa K, Tsuchiya E, Murata M, Sakiyama S, Nakamura Y (1992): Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res52: 873–877
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murata, M., Otsuka, M., Hayakawa, Y. et al. Expressivity of a common fragile site, fra(3)(p14.2), in patients with cancer and other diseases. Jap J Human Genet 37, 205–213 (1992). https://doi.org/10.1007/BF01900714
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01900714